L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats
- PMID: 9148009
- DOI: 10.1016/s0168-8278(97)80024-4
L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats
Abstract
Background/aims: The effect of L-ornithine (ORN) and L-ornithine-L-aspartate (OA) therapy on "extracerebral" nitrogen metabolism, brain metabolism and neurotransmission has been investigated in portacaval shunted rats with hyperammonemia-induced encephalopathy.
Methods: One day before ammonium-acetate infusion, a portacaval shunt was performed in three experimental groups: 1-control rats, 2-ORN-treated rats and 3-OA-treated rats. Ammonium-acetate was given as an intravenous bolus injection (0.4 mmol.kg bw-1) followed by a constant infusion (1.9 mmol.kg bw-1.h-1) so that steady-state blood ammonia concentrations (500-800 microM) were obtained in the course of 5 h. After 1 h, ammonium-acetate infusion, either L-ornithine or L-ornithine-L-aspartate, was infused for the next 4 h (3.0 mmol.kg bw-1.h-1) in the treated groups. The following parameters were measured: clinical grade of encephalopathy, EEG activity (n = 10 - 20/group), amino acids in plasma (n = 10 - 20/group) and brain dialysate (n = 5 - 9/group), and brain metabolites obtained by in vivo cerebral 1H-MRS (n = 4 - 6/group).
Results: ORN and OA treatment resulted in significantly lower blood (34% and 39%) and brain (42% and 22%) ammonia concentrations, significantly higher urea production (39% and 86%) and significantly smaller increases in brain glutamine and lactate concentrations than in controls. These changes were associated with a significantly smaller increase in clinical grade of encephalopathy in ORN- and OA-treated rats, and a significant improvement in EEG activity in ORN-treated rats. OA-treated rats showed a significant increase in aspartate and glutamate concentrations in brain dialysate.
Conclusions: The beneficial effects of both treatments on the manifestations of hyperammonemia-induced encephalopathy can be explained by a reduction in blood and brain ammonia concentrations. It is suggested that when OA is administered, the effect of ornithine is partly counteracted by aspartate, inducing high brain extracellular concentrations of the two excitatory amino acids glutamate and aspartate, and perhaps causing overstimulation of NMDA receptors.
Similar articles
-
The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy.J Hepatol. 1997 Feb;26(2):387-95. doi: 10.1016/s0168-8278(97)80057-8. J Hepatol. 1997. PMID: 9059962
-
L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action.Metab Brain Dis. 1998 Jun;13(2):147-57. doi: 10.1023/a:1020613314572. Metab Brain Dis. 1998. PMID: 9699922
-
Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate.Metab Brain Dis. 1996 Sep;11(3):229-37. doi: 10.1007/BF02237960. Metab Brain Dis. 1996. PMID: 8869943
-
Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy.Metab Brain Dis. 2002 Dec;17(4):453-62. doi: 10.1023/a:1021934607762. Metab Brain Dis. 2002. PMID: 12602521 Review.
-
Ornithine aminotransferase, a potential target for the treatment of hyperammonemias.Curr Drug Targets. 2000 Sep;1(2):119-53. doi: 10.2174/1389450003349254. Curr Drug Targets. 2000. PMID: 11465067 Review.
Cited by
-
Neuronal nitric oxide synthase and Hepatic Encephalopathy.Metab Brain Dis. 1998 Sep;13(3):175-89. doi: 10.1023/a:1023281307660. Metab Brain Dis. 1998. PMID: 9804363 Review. No abstract available.
-
Safety assessment of L-ornithine oral intake in healthy subjects: a systematic review.Amino Acids. 2025 May 5;57(1):23. doi: 10.1007/s00726-025-03455-4. Amino Acids. 2025. PMID: 40323503 Free PMC article.
-
Neuromonitoring in Rare Disorders of Metabolism.Yale J Biol Med. 2021 Dec 29;94(4):645-655. eCollection 2021 Dec. Yale J Biol Med. 2021. PMID: 34970103 Free PMC article. Review.
-
Contributions of microdialysis to new alternative therapeutics for hepatic encephalopathy.Int J Mol Sci. 2013 Aug 5;14(8):16184-206. doi: 10.3390/ijms140816184. Int J Mol Sci. 2013. PMID: 23921686 Free PMC article. Review.
-
Elevated cerebral lactate: Implications in the pathogenesis of hepatic encephalopathy.Metab Brain Dis. 2014 Dec;29(4):919-25. doi: 10.1007/s11011-014-9573-9. Epub 2014 Jun 11. Metab Brain Dis. 2014. PMID: 24916505 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical